ArticleBlood cancer journal2023

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.

Naseema Gangat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.